{"id":908454,"date":"2026-06-22T03:33:43","date_gmt":"2026-06-22T03:33:43","guid":{"rendered":"http:\/\/cri-one-origin-the-origin-of-the-alzheimers-mechanism-analysis-health-wellness-series-2017-invent-deposition-373"},"modified":"2026-06-22T03:33:43","modified_gmt":"2026-06-22T03:33:43","slug":"the-origin-of-the-alzheimers-mechanism-analysis-health-wellness-series-2017-invent-deposition-373-3","status":"publish","type":"post","link":"https:\/\/cri-one.com\/blog\/2026\/06\/22\/the-origin-of-the-alzheimers-mechanism-analysis-health-wellness-series-2017-invent-deposition-373-3\/","title":{"rendered":"The Origin of the Alzheimer’s Mechanism Analysis \u2014 Health & Wellness Series \u2014 2017 Invent Deposition #373"},"content":{"rendered":"

FIRST TO MARKET<\/strong> \u00b7 Publicly documented 2017 \u00b7 Invent Deposition #373<\/p>\n

Deposition #373<\/strong> is the origin of the disease-cure research line \u2014 the idea that a cure can be approached systematically, through toxic and valence testing<\/strong> of candidate compounds, across conditions including Alzheimer’s.<\/p>\n

\n

“a study of any cure by way of toxic and valance testing to include but not limited to cancer and diseases like alzheimer’s and substance abuse cessation aids” \u2014 Christopher Gabriel Brown, 2017<\/p>\n<\/blockquote>\n

From one line to an engineered product<\/h2>\n

The 2017 line sets the whole methodology: screen for a cure by toxicity and valence<\/strong> \u2014 which elements bind, which harm, which correct \u2014 rather than by trial alone. That method is the Alzheimer’s mechanism analysis: the computational pass over amyloid, tau, and neuroinflammation pathways with candidate compounds scored the same way. The founding claim is intact: test by valence and toxicity, let the chemistry name the cure.<\/strong><\/p>\n

Provenance<\/h2>\n